Your browser is no longer supported. Please, upgrade your browser.
CLDX Celldex Therapeutics, Inc. daily Stock Chart
Celldex Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.80 Insider Own0.22% Shs Outstand16.36M Perf Week-1.30%
Market Cap37.30M Forward P/E- EPS next Y-3.27 Insider Trans0.00% Shs Float15.21M Perf Month-8.43%
Income-49.80M PEG- EPS next Q-0.93 Inst Own27.00% Short Float1.75% Perf Quarter-2.15%
Sales4.50M P/S8.29 EPS this Y-10.70% Inst Trans4.32% Short Ratio2.05 Perf Half Y6.54%
Book/sh6.63 P/B0.34 EPS next Y15.10% ROA-34.50% Target Price19.00 Perf Year-55.90%
Cash/sh4.46 P/C0.51 EPS next 5Y- ROE-44.50% 52W Range2.01 - 6.43 Perf YTD2.24%
Dividend- P/FCF- EPS past 5Y1.10% ROI-125.40% 52W High-64.54% Beta3.46
Dividend %- Quick Ratio6.30 Sales past 5Y18.30% Gross Margin- 52W Low13.43% ATR0.10
Employees137 Current Ratio6.30 Sales Q/Q-44.40% Oper. Margin- RSI (14)46.70 Volatility3.55% 4.33%
OptionableYes Debt/Eq0.00 EPS Q/Q-12.50% Profit Margin- Rel Volume0.71 Prev Close2.31
ShortableYes LT Debt/Eq0.00 EarningsMar 05 AMC Payout- Avg Volume129.81K Price2.28
Recom2.00 SMA20-2.22% SMA50-3.06% SMA200-7.62% Volume92,294 Change-1.30%
Aug-01-17Resumed H.C. Wainwright Buy $10
Nov-07-16Initiated Aegis Capital Buy
Mar-08-16Downgrade Jefferies Buy → Hold
Mar-07-16Downgrade Wedbush Outperform → Neutral $4
Mar-07-16Downgrade Leerink Partners Outperform → Mkt Perform
Mar-07-16Downgrade Guggenheim Buy → Neutral
Mar-01-16Initiated H.C. Wainwright Buy $25
Aug-11-15Reiterated ROTH Capital Buy $43 → $39
Aug-11-15Reiterated Oppenheimer Outperform $45 → $42
Aug-11-15Reiterated Brean Capital Buy $35 → $31
Jun-02-15Reiterated WBB Securities Strong Buy $30 → $40
Nov-17-14Reiterated ROTH Capital Buy $40 → $43
Mar-04-14Reiterated Oppenheimer Outperform $40 → $36
Jul-08-13Reiterated Cantor Fitzgerald Buy $16 → $24
Mar-08-13Reiterated Cantor Fitzgerald Buy $13 → $16
Feb-26-13Reiterated Oppenheimer Outperform $10 → $13
Jan-10-13Reiterated Cantor Fitzgerald Buy $9 → $13
Oct-02-12Reiterated Oppenheimer Outperform $6 → $8
Sep-14-12Reiterated Cantor Fitzgerald Buy $7 → $9
Apr-04-12Initiated Cantor Fitzgerald Buy $7
Dec-23-19 10:26AM  Is Celldex Therapeutics, Inc. (CLDX) A Good Stock To Buy? Insider Monkey
Dec-12-19 11:30AM  Celldex (CLDX) Down 3.9% Since Last Earnings Report: Can It Rebound? Zacks
Nov-18-19 08:01AM  Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159 GlobeNewswire -5.95%
Nov-14-19 09:44AM  Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss Zacks
Nov-12-19 09:25AM  Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates Zacks
08:01AM  Celldex Provides Corporate Update and Reports Third Quarter 2019 Results GlobeNewswire
Nov-11-19 08:01AM  Celldex Presents Promising Data from CDX-0159 and CDX-527 Programs GlobeNewswire
Nov-08-19 07:30AM  CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study GlobeNewswire -9.16%
Oct-30-19 10:33AM  Will Celldex Therapeutics (CLDX) Report Negative Q3 Earnings? What You Should Know Zacks
Oct-02-19 08:01AM  Celldex Therapeutics Announces Upcoming Data Presentations GlobeNewswire
Sep-30-19 04:01PM  Celldex Therapeutics to Present at the Cantor Global Healthcare Conference GlobeNewswire
Sep-06-19 12:11PM  Edited Transcript of CLDX earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
09:31AM  Why Is Celldex (CLDX) Down 2.3% Since Last Earnings Report? Zacks
Aug-14-19 09:10AM  Kadmon (KDMN) Completes Enrollment in KD025 Study for cGVHD Zacks
Aug-13-19 11:53AM  Mallinckrodt Enrolls First Patient in Liver Disease Study Zacks +5.21%
09:50AM  Regeneron Ebola Treatment Shows Promise, Study Stopped Early Zacks
Aug-08-19 04:23PM  Celldex Therapeutics Inc (CLDX) Q2 2019 Earnings Call Transcript Motley Fool
10:54AM  Celldex (CLDX) Q2 Loss Narrower Than Expected, Revenues Miss Zacks
06:00AM  Celldex Therapeutics Keeps Up Its Penny-Pinching and Pipeline Progress Motley Fool
Aug-07-19 06:45PM  Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates Zacks
Jul-31-19 04:01PM  Celldex to Report Second Quarter 2019 Financial Results and Host Corporate Update Call GlobeNewswire
Jun-24-19 08:01AM  Celldex Therapeutics Appoints Diane C. Young, M.D. as Senior Vice President, Chief Medical Officer GlobeNewswire
Jun-06-19 09:31AM  Why Is Celldex (CLDX) Down 29.2% Since Last Earnings Report? Zacks
Jun-04-19 10:26AM  Celldex Presents Data From CDX-3379 Study at ASCO, Stock Down Zacks
07:45AM  The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer Benzinga
Jun-01-19 02:15PM  Celldex Announces Data from CDX-3379 Clinical Program Presented at ASCO 2019; Promising Biomarker Strategy Identified for Head and Neck Squamous Cell Carcinoma GlobeNewswire
May-26-19 05:03PM  The Week Ahead In Biotech: ASCO Presentations In The Spotlight Benzinga
May-14-19 12:36PM  Wall Street Sees 3 Falling Knives Rebounding Within 52 Weeks
May-08-19 07:00AM  Celldex Therapeutics Continues to Stretch Out Its Cash and Advance Its Pipeline Motley Fool
May-07-19 06:15PM  Celldex Therapeutics (CLDX) Reports Q1 Loss, Tops Revenue Estimates Zacks
05:09PM  Celldex: 1Q Earnings Snapshot Associated Press
04:01PM  Celldex Provides Corporate Update and Reports First Quarter 2019 Results GlobeNewswire
May-02-19 10:32AM  Celldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
Apr-06-19 09:30AM  Celldex (CLDX) Down 5.7% Since Last Earnings Report: Can It Rebound? Zacks
Apr-02-19 08:00AM  Celldex Presents Positive Interim Results from Phase 1 Study of CD40 Agonist CDX-1140 at American Association for Cancer Research (AACR) Annual Meeting 2019 GlobeNewswire -11.39%
Apr-01-19 01:00PM  Celldex Presents Promising Data from CDX-527 Bispecific and TAM Receptor Programs at American Association for Cancer Research (AACR) Annual Meeting 2019 GlobeNewswire
Mar-20-19 09:30AM  Is Celldex Therapeutics (CLDX) Stock Outpacing Its Medical Peers This Year? Zacks
Mar-13-19 01:19PM  Edited Transcript of CLDX earnings conference call or presentation 7-Mar-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-08-19 11:04AM  Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat Zacks +10.87%
07:45AM  Celldex Therapeutics' Cost-Cutting and Reverse Stock Split Help Keep It Rolling Motley Fool
Mar-07-19 07:44PM  Celldex Therapeutics, Inc (CLDX) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM  Celldex Provides Corporate Update and Reports Full Year 2018 Results GlobeNewswire
07:48AM  Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO Benzinga
Feb-22-19 05:50PM  Celldex Therapeutics (CLDX) Stock Sinks As Market Gains: What You Should Know Zacks
Feb-20-19 08:25AM  Analysis: Positioning to Benefit within Applied Materials, MRC Global, Meritor, Celldex Therapeutics, Quaker Chemical, and Cubic Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-14-19 10:45AM  The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna Zacks -6.51%
Feb-13-19 08:36AM  5 Tiny Biotech Stocks With Superb Growth Potential Zacks +10.82%
Feb-11-19 12:26PM  The Celldex Reverse Stock Split: What Investors Need To Know Benzinga -19.03%
09:55AM  Biotech Stocks To Watch ACCESSWIRE
Feb-08-19 11:45AM  Celldex Therapeutics Announces Reverse Stock Split GlobeNewswire -31.17%
Feb-05-19 09:20AM  4 Healthcare Stocks The Market is Watching on Tuesday (2/5/19) ACCESSWIRE -16.04%
08:30AM  Biotech Stocks to Watch ACCESSWIRE
Feb-04-19 02:35PM  These 4 Tech Stocks Could Set February Highs ACCESSWIRE +19.35%
Jan-29-19 08:30AM  Cannabis and Biotech Stocks that Could Explode ACCESSWIRE
Jan-23-19 08:30AM  Best Ways to Play Biotech Rally ACCESSWIRE
Jan-21-19 08:30AM  A Biotech Play You Can't Afford To Miss ACCESSWIRE
Dec-21-18 08:15PM  Here's Why Celldex Therapeutics Sank on Friday Motley Fool -13.08%
Dec-10-18 12:24PM  Why Celldex Therapeutics Is Jumping Today Motley Fool +6.61%
Nov-26-18 08:35AM  Analysis: Positioning to Benefit within Celldex Therapeutics, InnSuites Hospitality Trust, Keryx Biopharmaceuticals, EMX Royalty, FTE Networks, and Xinyuan Real Estate Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-10-18 08:01AM  Celldex Presents Emerging MerTK Antibody Program at the Society for Immunotherapy of Cancers 33rd Annual Meeting GlobeNewswire
Nov-09-18 08:12AM  Celldex (CLDX) Q3 Earnings Beat Estimates, Revenues Miss Zacks
08:01AM  Celldex Presents Promising Interim Data from Phase 1 Study of Differentiated CD40 Agonist CDX-1140 at the Society for Immunotherapy of Cancers 33rd Annual Meeting GlobeNewswire
Nov-08-18 05:48PM  Here's Why Celldex Therapeutics, Inc. Surged on Thursday Motley Fool +12.79%
08:45AM  Celldex Therapeutics Inc. Chugs Along in the 3rd Quarter Despite Challenges Motley Fool
Nov-07-18 06:55PM  Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates Zacks
05:49PM  Celldex: 3Q Earnings Snapshot Associated Press
04:01PM  Celldex Provides Corporate Update and Reports Third Quarter 2018 Results GlobeNewswire
Nov-01-18 03:51PM  Why Shares of Celldex Therapeutics, Inc. Sailed Higher Today Motley Fool +10.02%
Oct-22-18 03:18PM  Why Celldex Therapeutics, Inc. Fell on Monday Motley Fool -10.60%
Oct-09-18 07:50AM  Report: Developing Opportunities within Adamis Pharmaceuticals, Cass Information, Celldex Therapeutics, Par Pacific, Inovio Pharmaceuticals, and Liberty Global Future Expectations, Projections Moving into 2018 GlobeNewswire
Sep-18-18 09:04AM  What Investors Should Know About Celldex Therapeutics Incs (NASDAQ:CLDX) Financial Strength Simply Wall St.
Sep-07-18 09:30AM  Why Is Celldex (CLDX) Up 3.3% Since Last Earnings Report? Zacks
Aug-23-18 03:03PM  Why Celldex Therapeutics Inc. Shares Jumped on Wednesday Motley Fool -5.52%
08:00AM  Today's Research Reports on Trending Tickers: Celldex Therapeutics and Inovio Pharmaceuticals ACCESSWIRE
Aug-09-18 10:04AM  Celldex (CLDX) Q2 Earnings and Revenues Surpass Estimates Zacks -6.76%
06:30AM  Celldex Therapeutics, Inc. Spending Cuts Help Preserve Cash in the 2nd Quarter Motley Fool
Aug-08-18 07:50PM  Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates Zacks +5.18%
06:44PM  Celldex: 2Q Earnings Snapshot Associated Press
04:01PM  Celldex Provides Corporate Update and Reports Second Quarter 2018 Results GlobeNewswire
02:30PM  Celldex Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-02-18 08:01AM  Celldex to Report Second Quarter 2018 Financial Results and Host Corporate Update Call GlobeNewswire
Aug-01-18 07:45AM  Research Report Identifies Myriad Genetics, Celldex Therapeutics, Charles River Laboratories International, Louisiana-Pacific, Integrated Device Technology, and Beazer Homes with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire -5.48%
Jul-30-18 09:55AM  What's in Store for Celldex (CLDX) This Earnings Season? Zacks
Jul-27-18 07:35AM  Initiating Free Research Reports on Celgene and Three Other Biotech Equities ACCESSWIRE -5.89%
Jul-02-18 02:18PM  How David Gardner's Biggest Losers Demonstrate Why Long-Term Investing Wins Motley Fool
Jun-29-18 08:17AM  Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics Motley Fool
Jun-21-18 08:00AM  Complimentary Technical Snapshots on Celgene and Three More Biotech Stocks ACCESSWIRE
Jun-11-18 06:32AM  Celldex Therapeutics (CLDX) Down 9.2% Since Earnings Report: Can It Rebound? Zacks
Jun-02-18 04:12PM  Celldex Presents Promising Data from Phase 1/2 Study of Varlilumab and Opdivo® at 2018 ASCO Annual Meeting GlobeNewswire
Jun-01-18 11:30AM  Celldex Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-18-18 07:05AM  Audentes Therapeutics and Three More Stocks Under Scanner in the Biotech Space ACCESSWIRE
May-16-18 05:01PM  Celldex Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-15-18 02:43PM  May Insights Into Healthcare Stocks: Celldex Therapeutics Inc (NASDAQ:CLDX) Simply Wall St.
May-11-18 09:59AM  Celldex (CLDX) Q1 Loss Wider Than Expected, Shares Down Zacks
May-10-18 03:16PM  Celldex Therapeutics Moves Forward After Glemba Clinical Failure Motley Fool -6.48%
09:00AM  Celldex (CLDX) Q1 Loss Narrower, Revenues Beat, Shares Down Zacks
08:41AM  Celldex: 1Q Earnings Snapshot Associated Press
08:00AM  Celldex Provides Corporate Update and Reports First Quarter 2018 Results GlobeNewswire
May-03-18 10:24AM  What's in Store for Celldex (CLDX) This Earnings Season? Zacks
Apr-25-18 10:33AM  Lessons to Learn From April's Biotech Blowups Motley Fool
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. It develops CDX-1140, an agonist human monoclonal antibody, currently being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in multiple types of solid tumors and B cell lymphomas; CDX-3379, a human monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Erbitux; CDX-301, a dendritic cell growth factor; and Varlilumab, an immune modulating antibody targeting CD27 designed to enhance a patient's immune response. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; University of Southampton; Amgen Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.